Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

By M. Dudley, J. Wunderlich, Jie Yang, R. Sherry, S. Topalian, N. Restifo, R. Royal, U. Kammula, D. White, S. Mavroukakis and 11 more. Journal of Clinical Oncology, 2005

1,709 citations recorded by the source corpus.

Subfields: Dermatology, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/731f0554e189be38c42fe8b96a5364edae5170c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. S. Rosenberg
2. N. Restifo
3. Guido Kroemer
4. L. Zitvogel
5. M. Dudley

In Oncology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. Guido Kroemer
5. L. Zitvogel
6. Jie Yang
7. R. Sherry
8. U. Kammula

Citations in the corpus

• Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008, background): “Of patients with metastatic melanoma refractory to all other treatments, 50% will experience an objective response, some with complete response”
• Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. (2005, background): “For instance, chemotherapy, cyclophosphamide and other anti-cancer drugs, is currently used in preclinical and clinical studies either as anti-cancer therapy or in combination with cancer immunotherapy [67].”
• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens (2008, methodology): “Thus, the high response rates seen in the additional 58 patients reported here who received ACT with the NMA with or without additional TBI conditioning extend and confirm the high objective response rate reported by us earlier in 35 patients who received TIL transfer after the NMA conditioning regi”
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “CD19-28ζ+ T cells and thus their clinical benefits (8, 20, 21).”
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011, background): “Clinical trials in patients with metastatic melanoma have demonstrated the ability of adoptively transferred T cells to mediate durable complete cancer regression.(1,15,16) These results have stimulated efforts to genetically modify lymphocytes to improve their antitumor efficacy and to extend the r”